Statera Biopharma Top Management

STABDelisted Stock  USD 0.04  0.0003  0.82%   
Statera Biopharma employs about 46 people. The company is managed by 5 executives with a total tenure of roughly 108 years, averaging almost 21.0 years of service per executive, having 9.2 employees per reported executive. Analysis of Statera Biopharma's management performance can provide insight into the company performance.
George Wagner  Insider
Ex Affairs
Dr Buckheit  Insider
Chief Officer
  
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Statera Biopharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.2385) % which means that it has lost $0.2385 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.8694) %, meaning that it created substantial loss on money invested by shareholders. Statera Biopharma's management efficiency ratios could be used to measure how well Statera Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.

Statera Biopharma Workforce Comparison

Statera Biopharma is currently regarded as top stock in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 734. Statera Biopharma holds roughly 46.0 in number of employees claiming about 6% of stocks in Biotechnology industry.

Statera Biopharma Notable Stakeholders

A Statera Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Statera Biopharma often face trade-offs trying to please all of them. Statera Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Statera Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.

About Statera Biopharma Management Performance

The success or failure of an entity such as Statera Biopharma often depends on how effective the management is. Statera Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Statera management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Statera management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropeniaanemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the bodys immune system and restore homeostasis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 46 people.
Please note, the presentation of Statera Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Statera Biopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Statera Biopharma's management manipulating its earnings.

Statera Biopharma Workforce Analysis

Traditionally, organizations such as Statera Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Statera Biopharma within its industry.

Statera Biopharma Manpower Efficiency

Return on Statera Biopharma Manpower

Revenue Per Employee32.3K
Revenue Per Executive297.4K
Net Loss Per Employee2.2M
Net Loss Per Executive20.4M
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Other Consideration for investing in Statera Pink Sheet

If you are still planning to invest in Statera Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Statera Biopharma's history and understand the potential risks before investing.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation